Clinical Evaluation of a New Reduced Volume Bowel Preparation
Drug: macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Pilot Monocentric, Open Phase II Study to Investigate the Efficacy and Safety of a New Oral Gut Cleansing Solution ("Low Dose Bowel Prep") in 30 Patients Submitted to Colonoscopy|
- Efficacy measured by a final scoring system i.e., "the overall quality of colonoscopy prep" that will be graded (from A to C) and assessed from the degree of cleansing in a 0 - 4 grade scale for each of the predefined colon areas.
- Stool weight as recorded on the case report form for each stool as from start of gut cleansing (day -1) to the beginning of colonoscopy (day 0).
- Amount of fluid removed from the colon during the colonoscopy.
|Study Start Date:||January 2001|
|Estimated Study Completion Date:||May 2001|
Open prospective pilot monocentric phase II clinical trial evaluating the therapeutic efficacy of a new "Low Dose Bowel Prep" formulation for gut cleansing prior to colonoscopy.
Thirty patients admitted to the hospital (inpatients) planned to undergo a complete colonoscopy will have gut cleansing with the "Low Dose Bowel Prep" using a one-step intake mode.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00321230
|Hôpital Lariboisière, Endoscopy Department|
|Paris, France, 75010|
|Principal Investigator:||Alain Bitoun, MD||Hôpital Lariboisière|